Latest News about INCY
Recent news which mentions INCY
Second Setback For Incyte's LIMBER Program - Analyst Says 'Resolution Timelines Unclear To Assess Impact'
March 24, 2023
Tickers
INCY
From Benzinga
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
March 23, 2023
From Benzinga
From InvestorPlace
Why Shares of MacroGenics Climbed Thursday
March 16, 2023
From Motley Fool
Incyte Discontinues LIMBER-304 On Doubts Regarding Meeting Primary Goal, Analyst Says It Underpins Some Investor Concerns
March 06, 2023
Tickers
INCY
From Benzinga
Why the stock market rally can keep going, says Wall Street strategist who only recently warned of a death zone.
March 06, 2023
From MarketWatch
2 Steady Stocks to Buy in a Recession
February 03, 2023
From Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
January 31, 2023
From Benzinga
7 Biotech Stocks That Will Make You Rich in 10 Years
January 18, 2023
From InvestorPlace
Why These 7 Healthcare Stocks Could Soar in 2023
January 02, 2023
From InvestorPlace
2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond
December 29, 2022
From Motley Fool
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
December 18, 2022
From InvestorPlace
Cramer Says He's 'Always Liked' This Drug Company
December 16, 2022
From Benzinga
BriaCell's Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
December 13, 2022
From Benzinga
This fund beats the S&P 500 by using just 75 of its components. Here’s how it works.
December 08, 2022
From MarketWatch
7 Cash-Rich Stocks to Buy for Peace of Mind
November 04, 2022
Tags
NASDAQ:MRNA,NASDAQ:REGN,NASDAQ:ATVI,NASDAQ:CSGP,NYSE:GRMN,NASDAQ:INCY,NASDAQ:FSLR
Market News
FSLR
From InvestorPlace
2 Biotech Stocks That Could Make You Richer
November 04, 2022
From Motley Fool
Analyst Thinks This Company's Bone Marrow Cancer Treatment Can 'Transform Paradigm'
October 17, 2022
From Benzinga
2 Cathie Wood Stocks That Are Beating the Market This Year
October 07, 2022
From Motley Fool
Incyte Acquires Villaris Therapeutics, Deepening Portfolio For Immune-Mediated Dermatologic Diseases
October 03, 2022
Tickers
INCY
From Benzinga
MorphoSys' Monjuvi Shows Long-Term Durable Response In Blood Cancer Settings
September 29, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.